Amman, Mumbai : Axantia Holding (Axantia), a leading pharmaceutical company in the region operating through its pharmaceutical subsidiaries; Pharma International Company and Med City Pharmaceutical Industries announced today that it has entered into a License, Supply and Technology Sharing agreement with global pharma major, Lupin Limited (Lupin). Under the terms of Agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim Drug Product in certain territories including Saudi Arabia, certain GCC countries, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.
Lupin had earlier received the U.S. FDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta® (pegfilgrastim) through a filing using the 351(k) pathway.
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile
neutropenia in patients receiving chemotherapy.
-Ends-
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology
products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.
Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal|LinkedIn https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/
About Axantia
Axantia is a leading pharmaceutical company, established in 2014 as a joint venture between Abu Al Haj Family and Al Faisaliah Group. Axantia develops, manufactures, markets, and distributes high-quality branded generic pharmaceuticals and under-licensed products in 20 countries across the Middle East, Africa, and the CIS.
Axantia’s subsidiaries – Pharma International Company in Jordan and Med City Pharmaceutical Industries in Saudi Arabia are supported by functional organizations with different manufacturing lines to deliver a broad portfolio covering all major therapeutic areas. Axantia has a general formulations plant in Jeddah and has the renovated 3 plants in Amman Jordan; GF plant, Cepha plant and Injectable Cepha plant. Axantia is well-placed to be the partner of choice for companies looking to establish business in the MENA region.
Please visit www.Axantia.com for more information.
Follow us on LinkedIn: https://www.linkedin.com/company/axantiagroup
Facebook: https://www.facebook.com/Axantia
For further information or queries please contact –
Waheed Al Oran
Business Development and Strategy Director
Email: Waheed.AlOran@axantia.com
Shweta Munjal
Vice President & Global Head – Corporate Communications
Email: shwetamunjal@lupin.com
© Press Release 2022
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
